Welcome to our specialized iPSC-centric GMP facility that was designed for a single purpose:
to simplify and accelerate the journey of your allogeneic cell therapy from IND through clinical development
Where your innovation comes to grow
Our five Grade B and four Grade C suite GMP facility in Mont-Saint-Guibert, Belgium, combines your best with ours. You bring your desired edits and target product profiles, and we plug them into our exclusive Pulse™ and Echo™ Platforms. Through turnkey cell line development and cell therapy manufacturing support, we help you avoid time-consuming process transfers and position you to capitalize on our unique iPSCs and immunotherapy expertise.
For cell reprogramming, gene editing and MCB development
Our Pulse™ Platform for cell line development provides everything you need – the tools, the systems, the space, and the thinking – to drive toward your ideal clinical candidate.
- Cell reprogramming from a desired donor or donor material sourced by Cellistic
- Off-the-shelf, reprogrammed iPSCs available
- Multiplex gene editing, with up to three edits in one round
- Precise knockin, using CRISPR-mediated, homology-directed repair
- Delivering CRISPR components via RNP (ribonucleotide protein) complex to reduce off-target editing
- Full automatic clonality with UP.SIGHT
- Cryopreserved Master Cell Bank GMP manufacturing
For cell differentiation and expansion
Ideally suited for your Phase 1 and 2 studies up to a 50L scale, our Echo™ Platform for cell therapy differentiation and manufacturing relies on proven protocols that can help cut months – if not years – off your iPSC allogeneic development timeline.
- Established differentiation protocols for NK cell, T cells and macrophages
- Scale-up and optimization capabilities
- GMP facility with multiple suites in class A, B, and C
- Ability to manufacture clinical trial material (CTM) from a very small scale up to 50 L batches with high yield (above 75 billion cells)
- Feeder-free process to assist with scalability, reproducibility, and consistency
- Chemically refined medium
- Semi-automatic vial filling operations
Book your personal tour
Our Mont-Saint-Guibert facility is the first of its kind in Europe dedicated exclusively to iPSC cell therapy development and manufacturing. And while we think you will find it to be impressive, we think you will find the team running it to be even moreso. We would welcome an opportunity to introduce them and learn more about what is driving your interest in iPSC-based allogeneic cell therapy.